| Conferences \ Organ-on-a-Chip World Congress & 3D-Culture 2017 \ Organ-on-a-Chip and 3D-Culture: Companies, Technologies and Approaches \ Agenda \ Tommy Andersson |
| Register | Login |
Novel Microphysiological Multi-Organ Systems for Studies of Human Metabolic Diseases in Drug DiscoveryMonday, 10 July 2017 at 12:00  Add to Calendar ▼2017-07-10 12:00:002017-07-10 13:00:00Europe/LondonNovel Microphysiological Multi-Organ Systems for Studies of Human Metabolic Diseases in Drug DiscoverySELECTBIOenquiries@selectbiosciences.comCurrently used pre-clinical models often suffer from poor translation of drug responses to the patient due to the limited knowledge gained in the efficiency and mode of action of the drug candidate. This contributes to high attrition rates in early clinical programs. Multi organ-on-a-chip emulating human physiology have the possibility to improve success rate by mimicking the human disease state and improve selection of the right targets and compounds early in drug discovery. Such models will not only improve translation to patients but also reduce time spent in early clinical programs as well as reducing the needs for animal models. We developed a human liver - pancreatic islets chip model. The model allows cross talk between cells from both organs in a fluidic system and responds in a physiological way to glucose load by increased insulin secretion leading to increased glucose consumption (figure). Initial studies indicate that the model can become insulin resistant and thus can be used as a metabolic disease model. Ongoing studies are investigating how insulin resistance in liver cells effects islet function by using the insulin receptor antagonists. |
Add to Calendar ▼2017-07-10 00:00:002017-07-11 00:00:00Europe/LondonOrgan-on-a-Chip and 3D-Culture: Companies, Technologies and ApproachesSELECTBIOenquiries@selectbiosciences.com
